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Patients with hyperthyroidism were excluded from randomized clinical trials of oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation (NVAF). Whether direct oral anticoagulants (DOACs) are superior to warfarin in NVAF patients with hyperthyroidism remains unclear.
Methods 
We performed a nationwide retrospective cohort study using data from the Taiwan National Health Insurance Research Database.  We enrolled 1,600 and 903 NVAF patients with hyperthyroidism taking DOACs and warfarin, respectively, from June 1, 2012 to December 31, 2015. We used propensity score-based stabilized weights (PSSWs) to balance covariates across the study groups. Patients were followed up until the occurrence of study outcomes or study end (December 31, 2016).
Results   
We included 2,515 patients (mean age 69; 60% male) with NVAF and concomitant hyperthyroidism. After PSSW, the DOAC treated group (n=1,600) had comparable risks of ischemic stroke/transient ischemic attack (IS/TIA), intracranial hemorrhage, and all major bleeding when compared to the warfarin treated group (n=915). The DOAC group had a lower risk of major gastrointestinal bleeding (GIB) ([hazard ratio (HR):0.54; [95% confidential interval (CI):0.30-0.95]; P=0.0341) and all-cause mortality (HR:0.60; [95%CI:0.48-0.75]; P<0.0001) compared to the warfarin group. The lowered GIB or mortality with DOACs compared to warfarin was consistent across most subgroups, including dabigatran and rivaroxaban users. Among young patients (age <65 years), DOACs were associated with a higher risk of IS/TIA than warfarin (HR:2.42; [95%CI:1.04-5.64]; P=0.0401). We also used 1:4 matched to obtain the two study groups, both taking DOACs, with (n=1,600) and without hyperthyroidism (n=6400) based on CHA2DS2-VASc score. There were comparable risks of thromboembolism, major bleeding, and mortality between those NVAF patients with and without concomitant hyperthyroidism. 
Conclusion  















AF = Atrial fibrillation
ASMD = absolute standardized mean difference
CABG = coronary artery bypass graft
CHA2DS2-VASc score = congestive heart failure, hypertension, age 75 years or older for 2 points, diabetes mellitus, previous stroke/transient ischemic attack for 2 points, vascular disease, age 65-74 years, female gender
CI = confidential interval
CKD = chronic kidney disease
DOAC = direct oral anticoagulant 
GIB = gastrointestinal bleeding
HR = hazard ratio
ICD-CM = International Classification of Diseases, Clinical Modification
ICH = intracranial hemorrhage
INR = international normalized ratio 
IS/TIA = ischemic stroke or transient ischemic attack 
NHIRD = National Health Insurance Research Database
NVAF = non-valvular atrial fibrillation 
PCI = percutaneous coronary intervention
PSM = propensity score matching
PSSW = propensity score-based stabilized weight 







Both vitamin K antagonist oral anticoagulants (e.g. warfarin) and direct oral anticoagulants (DOACs) (e.g. apixaban, dabigatran, edoxaban, and rivaroxaban) are effective for stroke prevention among patients with non-valvular atrial fibrillation (NVAF) ADDIN EN.CITE 1. When DOACs were compared to warfarin in the pivotal trials, there was a reduction in stroke/systemic embolism, major bleeding and the risk of intracranial hemorrhage (ICH)  ADDIN EN.CITE 2-7. Therefore, the prescription of DOACs has been increasing substantially among the patients with NVAF, leading to a relative reduction in AF-related ischaemic stroke and mortality over the last 15 years. ADDIN EN.CITE 8, 9 Reversible causes of AF such as hyperthyroidism were part of the exclusion criteria of the major DOACs trials, and consequently, trial data on NVAF with hyperthyroidism are unavailable. Subclinical and overt hyperthyroidism are well-known risk factors for incident AF. ADDIN EN.CITE 10, 11 In patients with subclinical or overt hyperthyroidism, excess thyroid hormone shifts the haemostasis toward a hypofibrinolytic and hypercoagulable state, with a rise in levels of fibrinogen, von Willibrand factor, factors VIII and IX, and plasminogen activator inhibitor-1.12 The turnover of vitamin K–dependent clotting factors is also increased in patients with hyperthyroidism, which increases patient sensitivity to warfarin.13 Given the absence of literature on the effectiveness and safety of DOACs in NVAF patients with concomitant hyperthyroidism, we performed a nationwide cohort study to compare the effectiveness and safety of DOACs versus warfarin among NVAF patients with concomitant hyperthyroidism. Second, we compared the effectiveness and safety of DOACs between the NVAF patients with or without concomitant hyperthyroidism. 

Methods
The Taiwan National Health Insurance program is a compulsory universal health care system in Taiwan, which covers 23.72 million enrollees or about 99% of the population.  The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approval by the institutional review board of the Chang Gung Medical Foundation, Taiwan. Informed consent was waived due to the encrypted procedure for all personal information in the Taiwan National Health Insurance Research Database.
Study populations
A total of 44,949 patients with AF (International Classification of Diseases-the ninth revision Clinical Modification (ICD-9-CM) codes (427.31) taking any oral anticoagulant (e.g. apixaban, dabiagtran, rivaroxaban, or warfarin) were identified during the period from June 1, 2012 to December 31, 2015, because the first DOAC (dabigatran) was reimbursed by the Taiwan National Health Insurance program only since June 1, 2012. We excluded those patients age < 30 or > 100 years of age (n = 91), those patients had received joint replacement or valvular surgery (n = 1,981), or those patients with a diagnosis of cancer (n = 2,988). We defined hyperthyroidism associated AF as having the diagnosis of hyperthyroidism made from between 24 months prior, to until 3 months after, AF was diagnosed. There were 2,515 NVAF patients with concomitant hyperthyroidism identified, and a total of 1,600 and 915 patients were taking DOACs and warfarin, respectively. For those 37,386 NVAF patients without concomitant hyperthyroidism, there were 25,941 and 11,445 patients taking DOACs and warfarin, respectively (Figure 1). The index date was defined as the first date of prescribing DOACs or warfarin. The follow-up period started from the index date until the occurrence of any study outcome independently, or until the end date of the study period (December 31, 2016), whichever came first.
Study outcomes
We evaluated several study outcomes independently for DOACs versus warfarin among the NVAF patients with concomitant hyperthyroidism. We also reported the effectiveness and safety outcomes for those NVAF patients taking DOACs with concomitant hyperthyroidism versus those without concomitant hyperthyroidism. Study outcomes are ischemic stroke (IS)/transient ischemic attack (TIA), all-cause mortality, ICH, major gastrointestinal bleeding (GIB), and all major bleeding. To ensure the diagnostic accuracy, all study outcomes should be a discharge diagnosis. The NHIRD diagnosis codes were changed from ICD-9-CM to ICD-10-CM after January 1, 2016. The ICD-9-CM and ICD-10-CM codes that identify the study outcomes and the baseline covariates are summarized in Supplemental Table I. 
Covariates
 A history of myocardial infarction, congestive heart failure, ischemic stroke or transient ischemic event, percutaneous coronary intervention, coronary artery bypass surgery, hypertension, diabetes mellitus, peripheral arterial disease, hyperlipidemia, chronic kidney disease before the index date was identified. To reduce misclassification, at least two outpatient clinic or one discharge diagnosis was required. The CHA2DS2-VASc score (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, previous stroke/transient ischemic attack, vascular disease, age 65-74 years, female gender) was calculated as a measure of stroke risk. ADDIN EN.CITE 14 
Statistical analysis 
We used a propensity score-based stabilized weight (PSSW) method to balance the covariates across the DOAC (n = 1,600) and warfarin (n = 903) treated groups. ADDIN EN.CITE 15 The advantages of PSSWs are preserving the sample size of the original data to maintain the designated type I error, producing appropriate estimation of the variance of population average treatment effect (ATE). We also used a generalized boosted model (GBM) method to obtain the PSSWs for optimal balance among study groups. The advantage of GBM is automatically selecting which covariates to include and the best functional form including interactions.16 The baseline covariates in Table 1 were all included in the GBM, except for the CHA2DS2-VASc score, given that this was a combination of other covariates. Subgroup analysis was performed to determine whether each subgroup was associated with a consistent outcome versus warfarin as well as the main analysis. Of note, the PSSW was re-estimated for each subgroup analysis so that the DOAC group and the warfarin maintained a balance of varied covariates across groups. The balance of potential confounders at baseline (index date) between each study group were assessed using the absolute standardized mean difference (ASMD), and the value of ASMD ≤ 0.1 indicated an insignificant difference in potential confounders between the study groups. ADDIN EN.CITE 17
We also compared the effectiveness and safety of DOACs for those NVAF patients with hyperthyroidism (n = 1,600) versus those without hyperthyroidism (n = 25,941). Due to the large discrepancy of patient numbers between the two study groups, we used 1:4 propensity score matching (PSM) to obtain the 1,600 NVAF patients taking DOACs with hyperthyroidism and 6,400 NVAF patients taking DOACs without hyperthyroidism by baseline CHA2DS2-VASc score to eliminate the unbalanced demographic and comorbid medical disorders at index date between the two study groups.  
Annual incidence rates were calculated using the total number of study outcomes during the follow-up period divided by person-years at risk. The risk of study outcomes for DOACs versus warfarin (reference) among NVAF patients with hyperthyroidism or patients taking DOACs with hyperthyroidism versus those without hyperthyroidism (reference) was obtained by using the survival analysis (Cox proportional hazards regression for multivariate analysis). Statistical significance was defined as a P-value of < 0.05. All statistical analyses were performed by using SAS 9.4 (SAS Institute Inc., Cary, NC, USA). 

Results
DOACs versus warfarin among those patients with hyperthyroidism 
Among the 39,889 NVAF patients taking oral anticoagulants for stroke prevention, we identified a total of 1,600 and 915 patients with concomitant hyperthyroidism taking NOACs and warfarin, respectively (Figure 1). Among the DOAC group, there were 129, 708, and 763 patients taking apixaban, dabigatran, and rivaroxaban, respectively. Of these, 55% (n = 71), 88% (n = 626), and 93% (n = 706) were taking low-dose apixaban (2.5 mg twice daily), dabigatran (110 mg twice daily), and rivaroxaban (10-15 mg once daily), respectively.
Before PSSW, the DOAC group had a higher prevalence of age, hypertension, diabetes, dyslipidemia, female in gender, and a higher CHA2DS2-VASc score than the warfarin group. After PSSWs, both study groups were well-balanced in all characteristics (all ASMD < 0.1) (Table 1). After PSSW, the annual incidences of IS/TIA, ICH, and all major bleeding were comparable between the DOAC and warfarin groups. The DOAC group had a significantly lower risk of major GIB (0.74%/year vs. 1.18%/year; hazard ratio (HR): 0.54; 95% confidential interval (CI): [0.30-0.95]; P = 0.0341) and all-cause mortality (5.34%/year vs. 7.87%/year; HR: 0.60; 95%CI: [0.48-0.75]; P < 0.0001) when compared to the warfarin group (Table 2 and Figure 2). 
Subgroup analysis 
For the different DOAC subgroups, only rivaroxaban (n = 662) was associated with a lower risk of major GIB than warfarin (n = 903) (HR: 0.42; 95%CI: [0.18-0.96]; P = 0.0395). Both dabigatran (n = 626) (HR: 0.58; 95%CI: [0.44-0.77]; P = 0.0001) and rivaroxaban (HR: 0.58; 95%CI: [0.44-0.78]; P = 0.0002) were associated with a lower mortality than warfarin (Figure 2). The age subgroup analysis found that DOACs (n = 425) were associated with a higher risk of IS/TIA than warfarin (n = 510) (HR: 2.42; 95%CI: [1.04-5.64]; P = 0.0401) among younger patients (age < 65 years), while the other age subgroups showed consistent results for effectiveness and safety with among those patients with hyperthyroidism the main analysis (Figure 3). Male patients taking DOACs (n = 595) had a lower risk of major GIB than those taking warfarin (n = 417) (HR: 0.28; 95%CI: [0.09-0.82]; P = 0.0198) (Supplemental Figure I). Also, patients with concomitant diabetes taking DOACs (n = 563) had a lower risk of major GIB (HR: 0.39; 95%CI: [0.16-0.98]; P = 0.0442) and all major bleeding (HR: 0.52; 95%CI: [0.27-0.99]; P = 0.0474) compared to warfarin (n = 244) (Supplemental Figure II).
Hyperthyroidism versus non-hyperthyroidism in patients taking DOACs




To the best of our knowledge, this is the largest real-world cohort evaluating the effectiveness and safety of DOACs among NVAF patients with concomitant hyperthyroidism. Our study has three major conclusions, as follows: (i) among NVAF patients with concomitant hyperthyroidism, DOAC use was associated with a comparable risk of thromboembolism and a significantly lower risk of major gastrointestinal bleeding and all-cause mortality when compared to warfarin; (ii) patients aged < 65 years taking DOACs were associated with a higher risk of IS/TIA than those taking warfarin; and (iii) there was a comparable risk of thromboembolism, major bleeding, and mortality between those NVAF patients with and without concomitant hyperthyroidism. Our study suggests that DOACs may be an effective and safer alternative to warfarin among NVAF patients with concomitant hyperthyroidism. Furthermore, hyperthyroidism did not affect overall outcomes related to DOACs in NVAF patients with concomitant hyperthyroidism. However, DOACs may be associated with a higher risk of thromboembolism than warfarin among younger NVAF patients age < 65 years with concomitant hyperthyroidism.
     Hyperthyroidism related AF is often regarded as reversible, ADDIN EN.CITE 18 and AF recurrence after correcting underlying thyroid abnormality is considered less likely in contrast to other medical conditions related to AF. Therefore, long-term anticoagulation therapy may be unnecessary in the AF patient group with concomitant hyperthyroidism, in the absence of other stroke risk factors. However, it remains unclear whether hyperthyroidism-related AF carries a higher risk of ischemic stroke compared to non-thyroid disease related AF. ADDIN EN.CITE 19 Excessive thyroid hormone may result in abnormal homeostasis and a hypercoagulable status among those patients with subclinical or overt hyperthyroidism.12 However, contemporary guidelines do not incorporate hyperthyroidism as an additional stroke risk factor in NVAF. ADDIN EN.CITE 14 Indeed, studies focusing on hyperthyroidism associated AF stroke are limited. One small prospective study in hyperthyroid patients with a new-onset AF, reported an increased risk of ischemic stroke clustering during the initial presentation, suggesting prompt early use of anticoagulation therapy in such hyperthyroid patients with AF. ADDIN EN.CITE 20 Another study focused on the benefit of anticoagulation therapy in hyperthyroidism related AF concluded that warfarin was still beneficial compared to aspirin or no-treatment, but only for those AF patients with CHA2DS2-VASc score of ≥ 1. ADDIN EN.CITE 18  Until now, there have been no RCTs specifically focused on AF patients with concomitant hyperthyroidism in relation to the efficacy and safety of long-term anticoagulation therapy. 
Previous studies indicated that DOACs are at least as effective as warfarin in reducing thromboembolism, with a  lower risk of ICH and major bleeding.  ADDIN EN.CITE 2-7 The efficacy and safety of DAOCs have also be studied in NVAF patients in association with several difficult treatment scenarios including the elderly, chronic kidney disease, valvular heart disease, or ischemic heart disease.21 Reversible causes of AF, including untreated hyperthyroidism, were exclusion criteria in the pivotal RCTs of DOACs.  ADDIN EN.CITE 3-7 One disadvantage of DOACs may be the lack of validated tests to monitor serum and clinical anticoagulation effects in the conditions of altered pharmacodynamics such as hyperthyroidism.22  This is relevant since hyperthyroidism causes an increased sensitivity to the anticoagulant effects of warfarin, with a lower factor II activity and shorter partial thromboplastin time with kaolin (PTT-K) observed when compared to the euthyroid patients [ref]. Warfarin administration resulted in a further decrease in factors II and VII and greater increase in PTT-K in patients in a hyperthyroid state as compared to those in an euthyoid state.23 This may lead to higher risk of major bleeding if warfarin dosages are not adjusted appropriately.13
As far as we are aware, there are no published data on the effectiveness and safety of DOACs in AF patients with concomitant hyperthyroidism. Given that the direct dependence on vitamin K–related clotting factors such as factor II of the DOACs (particularly with dabigatran) whether a similar increase in drug sensitivity in DOACs as with warfarin, remains unclear. NVAF patients with concomitant hyperthyroidism taking warfarin may have better clinical outcomes than those taking antiplatelet therapy or non-treatment. ADDIN EN.CITE 18  Our present study shows for the first time that DOACs have a comparable effectiveness and a better safety profile than warfarin in NVAF patients with concomitant hyperthyroidism. Furthermore, patients taking DOACs with hyperthyroidism showed broadly similar effectiveness and safety profiles compared to those without hyperthyroidism.  However, we unexpectedly found a higher risk of IS/TIA for DOACs versus warfarin among younger NVAF patients (age < 65 years). Recent real-world data showed a high prevalence of prescriptions of “low-dose” DOACs in NVAF patients worldwide. ADDIN EN.CITE 24-27 In the present study, a high percentage (88%) of NVAF patients with concomitant hyperthyroidism taking low-dose DOACs was also observed, and inappropriate prescriptions of low-dose DOACs without following the prescribing label or guideline recommendations may result in more thromboembolic events, while failing to reduce the risk of major bleeding. ADDIN EN.CITE 24 The prescription of “low-dose” DOACs in the younger population may lead to inadequate anticoagulation. 
Limitations
There are several limitations to this study. First, several important clinical parameters are not available in the NHI claims database, including imaging information, smoking history, LDL-cholesterol, serum renal and liver function, and electrocardiography, and those factors may contribute to the unmeasured confounders in the present study. Second, the diagnosis of hyperthyroidism is dependent on the diagnosis of ICD coding input by each physician taking responsibility. Due to the lack of the important laboratory data such as serial TSH and free T4 levels, we cannot evaluate the thyroid status of each patient with hyperthyroidism, or whether their hyperthyroid status has changed to an euthyoid status after appropriate treatment. In addition, whether the electrocardiographic rhythm of atrial fibrillation was converted back to the sinus rhythm after any medical/electrical intervention or correction of hyperthyroidism was unknown. Third, miscoding and misclassification of the baseline comorbidities and outcomes registered by each physician’s choice of treatment are additional limitations of the present study. In order to minimize the potential confounding bias, only primary discharge diagnoses of outcomes were considered. Fourth, there was a large discrepancy of the baseline covariates between the DOAC and warfarin group among the patients with hyperthyroidism. We used PPSWs instead of inverse probability of treatment weighting (IPTW) in analyzing data obtained from the present study. The advantage of PSSW over IPTW is to preserve the sample size of the original data. In addition, use of PSSW can reduce the weights of either those untreated subjects with high propensity scores or those treated subjects with low propensity scores in the pseudo data sets. Therefore, the results using PSSW are robust even with few observations with extreme IPTWs. ADDIN EN.CITE 15 Although PSSW allowed the matching of baseline comorbidities among the study groups, selective prescribing behavior and residual confounding factors cannot be excluded. Finally, edoxaban was not included in the present study because it was not approved in Taiwan until October 1, 2016.

Conclusion
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Figure 1. Enrollment of NVAF patients with/without concomitant hyperthyroidism.
From June 1, 2012, to December 31, 2015, 1600 and 915 patients with concomitant non-valvular atrial fibrillation (NVAF) and hyperthyroidism taking direct oral antagonists (DOACs) were enrolled in the study. There were other 25,491 and 11,445 NVAF patients without hyperthyroidism taking direct oral antagonists (DOACs) during the same study period. The method of propensity score-based stabilized weight (PSSW) was used to balance the covariates across the DOAC (n = 1,600) and warfarin groups (n = 903) among those patients with hyperthyroidism. In addition, 1:4 propensity score matching (PSM) was used to obtain the 1,600 NVAF patients taking DOACs with hyperthyroidism and 6,400 paired NVAF patients taking DOACs without hyperthyroidism.

Abbreviation: 
AF = atrial fibrillation; DOAC = direct oral anticoagulant. NVAF = non-valuvlar atrial fibrillation; PSM = propensity score matching; PSSW = propensity score-based stabilized weight

Figure 2. Forest plot of hazard ratio (HR) for direct oral anticoagulants (DOACs) versus warfarin among non-valvular atrial fibrillation (NVAF) patients with concomitant hyperthyroidism after propensity score stablized weighting (PSSW). 
DOAC was associated with a comparable risk of ischemic stroke/transient ischemic attack (IS/TIA), intracranial hemorrhage (ICH), major bleeding, and a lower risk of major gastrointestinal bleeding (GIB) and all-cause mortality than warfarin among those NVAF patients with concomitant hyperthyroidism. The subgroup analysis indicated that both dabigatran and rivaroxaban showed a significantly lower risk of morality than warfarin. Rivaroxaban was associated with a significantly lower risk of major GIB than warfarin.

Abbreviations: 
DOAC = direct-oral anticoagulant; GIB = gastrointestinal bleeding; HR = hazard ratio; ICH = intracranial hemorrhage; IS/TIA = ischemic stroke/transient ischemic attack; NVAF = non-valvular atrial fibrillation; PSSW = propensity score stabilized weighting.

Figure 3. Forest plot of HR for DOACs versus warfarin among NVAF patients with concomitant hyperthyroidism according to different age subgroup after PSSW. 
For different age subgroup, it is noted that DOAC was associated with a higher risk of ischemic stroke/transient ischemic attack (IS/TIA) than warfarin among those young patients of < 65 years of age, while other age subgroups showed a consistent result of effectiveness and safety outcomes as well as the main analysis.

Abbreviations: 
DOAC = direct-oral anticoagulant; GIB = gastrointestinal bleeding; HR = hazard ratio; ICH = intracranial hemorrhage; IS/TIA = ischemic stroke/transient ischemic attack; NVAF = non-valvular atrial fibrillation; PSSW = propensity score stabilized weighting.

Figure 4. Forest plot of HR for NVAF patients taking DOACs with concomitant hyperthyroidism versus those without hyperthyroidism after propensity score matching (PSM). 
Patients taking DOACs with hyperthyroidism were associated with a comparable risk of all outcomes to those without hyperthyroidism. The subgroup analysis indicated that all DOACs were associated with a comparable risk of effectiveness and safety outcomes between those patients taking DOACs with hyperthyroidism and without hyperthyroidism.

Abbreviations: 







Baseline characteristics of non-valvular atrial fibrillation (NVAF) patients with concomitant hyperthyroidism taking oral anticoagulants before and after propensity score stabilized weighting (PSSW)
	Before PSSW		After PSSW
	HyperthyroidismDOAC	HyperthyroidismWarfarin	ASMD		HyperthyroidismDOAC	HyperthyroidismWarfarin	ASMD





































Number of events, crude and adjusted event rates among NVAF patients with concomitant hyperthyroidism taking direct oral anticoagulants (DOACs) versus warfarin
Before PSSW
　	NVAF patients with hyperthyroidismDOAC	NVAF patients with hyperthyroidismWarfarin	Cox regression model
	(n = 1,600)	(n = 915)	





All major bleeding	43	1.51%/y	32	1.40%/y	0.93; [0.59-1.48]	0.7594
After PSSW
　	NVAF patients with hyperthyroidismDOAC	NVAF patients with hyperthyroidismWarfarin	Cox regression model
	(n = 1,600)	(n = 915)	





All major bleeding	40	1.40%/y	38	1.72%/y	0.71; [0.45-1.12]	0.1382
CI = confidential interval; DOAC = direct-oral anticoagulant; GIB = gastrointestinal bleeding; HR = hazard ratio; ICH = intracranial hemorrhage; IS/TIA = Ischemic stroke or transient ischemic attack; NVAF = nonvalvular atrial fibrillation; PSSW = propensity score stabilized weighting

Table 3
Baseline characteristics of NVAF patients taking DOACs with concomitant hyperthyroidism versus those without concomitant hyperthyroidism  before and after propensity score matching (PSM)
	Before PSM		After PSM
	Hyperthyroidism	No hyperthyroidism	ASMD		Hyperthyroidism	No hyperthyroidism	ASMD






































Number of events, crude and adjusted event rates among NVAF patients taking DOACs with concomitant hyperthyroidism taking DOACs versus those without concomitant hyperthyroidism 
Before PSM
　	Hyperthyroidism	No hyperthyroidism	Cox regression model
	(n = 1,600)	(n = 25,941)	





All major bleeding	43	1.51%/y	804	1.76%/y	0.86; [0.63-1.17]	0.3264
After PSM
　	Hyperthyroidism	No hyperthyroidism	Cox regression model
	(n = 1,600)	(n = 6,400)	





All major bleeding	43	1.51%/y	187	1.68%/y	0.90; [0.65-1.26]	0.5395

PSM = propensity score matching.  Other abbreviations as in Table 2.
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